证券研究报告：医药生物|深度报告 发布时间：2025-07-04 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7754.01 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 | 周最低 | 6070.89 | 行业相对指数表现（相对值） 2024-07 2024-09 2024-11 2025-02 2025-04 2025-06 -9% -5% -1% 3% 7% 11% 15% 19% 23% 27% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《国家药监局审议通过《关于优化全 生命周期监管支持高端医疗器械创新 发展的举措》，高端医疗器械发展有望 提升》 - 2025.06.30 RDC 引领核药行业快速崛起，开启诊疗一体化时代 l RDC 关注度持续提升，国内核药行 ...

2025年RDC药物最新进展。在医学不断进步的今天，肿瘤治疗领域持续探索更精准、高效且低毒的治疗方法。放射性核素偶联药物（RDC）作为核药领域 的前沿方向，凭借其精准靶向、高效杀伤和诊疗一体化的独特优势，近年来正在全球医药领域掀起创新浪潮。 一、厚积薄发，RDC药物的崛起 自1896年贝克勒尔首次发现放射性物质，开启了放射性核素在医学领域应用的探索之旅，至今已逾一个多世纪。在这漫长的发展历程中，放射性核素在医学 领域的应用范围不断拓展，尤其是在核药领域取得了显著进展。其中，诊断用途的核药在核药应用市场中占据主导地位，占比超过九成。 进入21世纪，传统核药如碘-131（碘化钠）、镭-223（氯化镭）等在临床治疗中得到广泛应用。碘-131自1941年首次用于治疗甲状腺功能亢进取得良好效果 后，1946年又被应用于甲状腺癌的治疗，大量临床研究证实其治疗分化型甲状腺癌转移灶疗效好、操作简便且副作用小。2013年，拜耳的Xofigo（氯化镭 [223Ra]注射液）成功获得FDA批准上市，成为历史上首个治疗用核药，用于治疗前列腺癌骨转移。 放射性药物分类及特点 图片来源：摩熵咨询《中国放射性药物产业白皮书》 近年来，以镥 ...

Group 1 - The Henan Kaifeng Ruida Pharmaceutical Technology Company has achieved results in the major scientific and technological project "Research and Clinical Application of New Targeted (Innovative) Drugs for Malignant Tumors" [1] - The innovative drug RDc001 has received approval for clinical trials, supported by local government policies [1] - The company focuses on biopharmaceutical research, particularly in high-tech cancer-targeted drug projects, which require significant funding and have long development cycles [1] Group 2 - Kaifeng City has implemented a "loan-equity linkage" model to support enterprises, establishing a science and technology innovation fund to provide equity investment [1] - In the first quarter, the number of banks cooperating with the "Bian Ke Loan" program expanded to five, enhancing financial services for technological innovation [1] - Kaifeng's high-tech industry added value accounted for a significant portion of the province's industrial output, with 333 high-tech enterprises reported [1] Group 3 - The Kaifeng Shunhe Hui Autonomous District is home to the Kaifeng Times New Energy Technology Company, which focuses on core technologies for all-vanadium flow batteries [2][3] - The district has successfully cultivated several high-tech enterprises, including Deerl Air Separation and Kaifeng Times, through a collaborative model involving leading enterprises, research institutions, and innovation teams [3] - Kaifeng has secured 13 provincial science and technology projects this year, including an "AI + new materials" project by Aitu Environmental Technology Company [3]

睿智医药 20250622 睿智医药在 2025 年第一季度的业绩表现如何？ 2025 年第一季度，睿智医药实现收入 2.61 亿元，同比增长 11.37%。归属于 上市公司股东的净利润为 664.21 万元，同比扭亏为盈；扣非归母净利润为负 公司小分子药物业务增长乏力，大风险相关业务增长较快；国内增速提 升，特别是近期几个大项目带动行情；海外市场景气度回升，资金流回 一级市场。 公司通过参与投资基金，以少量资金撬动政府引导基金进行早期孵化， 获取整包订单，并参与后端收益分成；同时，通过股权收购补足整包环 节空缺。 157.10 万元，同比减亏 94%。公司在第一季度迎来了重要的业绩拐点。 睿智医药采取了哪些战略措施来提升业绩？ 睿智医药从以下三个方面执行和突破业务：全面推动整包战略，以差异化解决 方案突破同质化竞争格局，为客户提供从 IND 到 PCC 的一站式解决方案，提 高研发效率并降低成本和风险；强化全链条整包服务能力，提升订单规模和客 户粘性，同时增加高附加值订单占比以提升盈利能力；规划补充产业链关键环 节，以延展业务服务领域纵向覆盖广度及技术深度，为客户提供更加灵活综合 的药物开发解决方案。此外， ...

Core Insights - Giftify, Inc. has announced the strategic acquisition of TakeOut7, enhancing its digital commerce ecosystem with comprehensive restaurant ordering and AI-powered marketing solutions [1][5] - The acquisition is valued at 350,000 shares of Giftify common stock and aims to connect over 185,000 restaurants with advanced technology [1][8] Comprehensive Restaurant Technology Solution - TakeOut7 operates two platforms: an online ordering platform with a "zero cost" business model and an AI-powered marketing platform called Platr [3][4] - The ordering platform charges consumers a nominal fee of $1.99 while providing a complete technology suite for restaurants, ensuring scalability and reliability through AWS serverless architecture [3][4] Strategic Value and Market Opportunity - The acquisition positions Giftify to tap into the $1.5 billion restaurant digital marketing market, targeting around 200,000 independent restaurants with annual sales over $1 million [5] - A significant percentage of restaurant operators (90%) express concerns that lack of marketing negatively impacts sales, and 84% lack the time or budget for effective marketing initiatives [5] Management Commentary - The CEO of Giftify, Ketan Thakker, emphasized that the acquisition expands the company's technology platform and market reach, creating a comprehensive ecosystem for independent restaurants [6] - The integration of TakeOut7's technology with Restaurant.com enhances the value proposition for restaurant partners by providing essential operational tools [6] Enhanced Platform Capabilities - TakeOut7's platforms have generated over $300 million in trackable sales for restaurant clients and will expand Giftify's restaurant network to over 185,000 establishments [8] - The acquisition is expected to provide immediate access to a POS dealer network of over 50 sales offices across the U.S. [8] Financial Impact and Integration - TakeOut7's platforms generate an average revenue of $2,500 per restaurant annually, and the acquisition is anticipated to positively impact Giftify's financial performance immediately upon integration [9][10] - Giftify plans to leverage its existing restaurant relationships to accelerate the growth of TakeOut7's dual-platform solution [10]

The new BNPL integration is designed to make CardCash even more accessible to shoppers who want to save money while maintaining flexibility in how they pay. Buy Now, Pay Later solutions have gained significant popularity in recent years, especially among Millennials and Gen Z consumers seeking alternatives to traditional credit. The BNPL model has seen substantial growth amid inflation and economic uncertainty, as consumers look for ways to better manage their cash flow. By incorporating this payment model, ...

文/曹萌 5月19日， 2025年的网络情人节"520"即将到来，而在这男女表达爱意的时点，大西洋彼岸传来一 则有关美国前总统拜登的噩耗，他被确诊为前列腺癌。 援引央视新闻，根据拜登办公室发布的一份声明， 拜登被确诊患有恶性前列腺癌，癌细胞已扩散至 骨骼。 声明指出，拜登上周因泌尿系统症状加剧而新发现一个前列腺结节，医生在进一步评估后于 16日诊断拜登患有前列腺癌。 此外，声明称，虽然这是一种更具侵袭性的癌症，但这种癌症似乎对激素敏感，因此可以进行有效治 疗，拜登及其家人正在与他的医生共同探讨治疗方案。 对于拜登出现的新病情，美国现任总统特朗普送上了早日康复的祝愿。如此来看，虽然美国男性总统 可以前赴后继的涌现，但他们的前列腺却只有一个，需格外呵护。 "男人至死是少年"是一句当下流行的网络用语 ，但对于那些已经步入知天命的男人来说，内心深处 留存的纯真、热血还能保留多少，尚未可知。而他们却已被列为前列腺癌的高发人群。 从前列腺癌的治疗方式分析，目前主要包括：药物治疗、手术治疗和放射治疗等。而在A股和港股 中，也有一些相关的上市公司，例如，奥翔药业生产的前列腺素类产品，在2024年的营收为2208万 元，同比下 ...

白交 克雷西 发自 凹非寺 量子位 | 公众号 QbitAI 一夜之间，老黄天塌了（doge）。 全球首个分布式RL训练模型 INTELLECT-2 发布，它仅通过整合全球闲置或分散的计算资源，就完成了模型的强化学习训练，训练成本大大 降低。 其模型性能与DeepSeek-R1媲美！ 一旦范式成立，这也就意味RL训练摆脱了对集中式算力的依赖，世界上任何一个人都可以参与到模型训练当中，大公司垄断算力时代可能就 此终结。 Just like this~算力来算力来，算力从四面八方来。 此模型版本有19个人/机构提供了算力资源支持（源自模型回答，还包括它自己） 除了贡献算力，还有不少大佬愿意投钱，包括不限于Karpathy大神、FlashAttention作者Tri Dao大神、HuggingFace联创兼CEO Clem Delangue等等。 据团队成员介绍，他们从编写模型强化学习框架 prime-rl ，到今天发布大概 只用了两个月时间 。 目前基础设施已到位，并且经过验证，超过那些先进实验室只是时间问题。 （比如OpenAI？） 有人已经开始断言：未来的顶级开源模型将以分布式方式进行训练。 INTELLEC ...

Platform Reports Up to 37% Discounts on NBA Store Cards as Playoff Viewership Surges 13% Year-Over-Year SCHAUMBURG, IL, May 08, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ: GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced that its subsidiary CardCash.com is experiencing substantial transaction volume growth during the ongoing sports playoff season, driving increased user acquisition for the Company. With ...

AI-Powered Digital Transformation Accelerates Growth Potential in Leading Gift Card Marketplace SCHAUMBURG, IL, April 29, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ: GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the strategic expansion of Artificial Intelligence (AI) tools across its operations to streamline internal processes, minimize manual workload, and support faster, data-driven decision-making ...